Tirzepatide vs Semaglutide for Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction
Data Collection
Collected from past medical records and data - RetrospectiveCardiovascular Diseases+6
+ Diabetes Mellitus
+ Diabetes Mellitus, Type 2
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Summary
Study start date: January 1, 2025
Actual date on which the first participant was enrolled.This study is designed to compare the effectiveness of two medications, tirzepatide and semaglutide, in adults with type 2 diabetes and a specific type of heart failure known as heart failure with preserved ejection fraction (HFpEF). Both medications are already approved for controlling blood sugar levels and aiding weight loss in people with type 2 diabetes and obesity. Obesity is a major risk factor for developing heart failure, particularly HFpEF. By understanding how these drugs work in people with type 2 diabetes and HFpEF, the study aims to improve treatment strategies and possibly reduce symptoms and events related to heart failure. Participants in this study are adults over 18 years old who have type 2 diabetes and HFpEF and have recently started taking either tirzepatide or semaglutide. Researchers will collect information about participants from insurance records, including their medical history and treatment details. The study will track participants from the day after they begin their medication until certain events occur, such as hospitalization due to heart failure or death from any cause. The study will analyze results using statistical methods to understand the risk and benefits of each medication, focusing on how they impact heart failure-related hospitalizations and overall survival.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.26000 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Conditions
Pathology
Criteria
Inclusion Criteria: * Patients who are new users of tirzepatide or new users of semaglutide * Patients with diagnosis of T2D and HFpEF, i.e., EF \>= 45%. * Age \>= 18 years old * Patients with continuous health plan enrollment before and including the treatment initiation date Exclusion Criteria: * Patients with missing age or sex information * Patients with type 1 diabetes mellitus, secondary or gestational diabetes * History of diabetes related complications * Patients with related chronic diseases. * History of gastrointestinal conditions. * Previous exposure to other GLP-1RA and pramlintide * Patients with prescription dispensing for both tirzepatide and semaglutide on cohort entry date
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location